Trials / Unknown
UnknownNCT03374280
Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC
The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Guangzhou Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC
Detailed description
In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of pemetrexed. So we design the trial to investigate curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pemetrexed/cisplatin intercalating gefitinib | |
| DRUG | pemetrexed/cisplatin |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-12-30
- Completion
- 2021-12-30
- First posted
- 2017-12-15
- Last updated
- 2019-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03374280. Inclusion in this directory is not an endorsement.